Drug Profile


Alternative Names: MRX-4

Latest Information Update: 28 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Morria Biopharmaceuticals
  • Developer Celsus Therapeutics
  • Class Anti-inflammatories
  • Mechanism of Action Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Allergic rhinitis

Most Recent Events

  • 06 Mar 2013 Morria Biopharmaceuticals is now called Celsus Therapeutics
  • 31 Dec 2012 Celsus Therapeutics plans a phase IIb trial for Allergic rhinitis in Austria
  • 17 Jun 2010 Final safety and efficacy data from a phase II trial in Allergic rhinitis released by Morria Biopharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top